Home > Healthcare > Drug Device Combination > Therapeutic Systems > Dacryocystitis Market

Dacryocystitis Market Trends

Report ID: GMI9588
Published Date: May 2024
Report Format: PDF

Download Free Sample

Dacryocystitis Market Trends

Advancements in imaging technologies like high-resolution ultrasound, magnetic resonance imaging, and computed tomography are enhancing the accuracy and precision of dacryocystitis diagnosis. These sophisticated imaging methods allow medical professionals to visualize the lacrimal drainage system, detect anatomical irregularities or blockages, leading to prompt identification and treatment of dacryocystitis.
Rising concerns about antibiotic resistance has resulted into an increased focus on antibiotic stewardship in the treatment of dacryocystitis. Medical practitioners are implementing strategies to optimize antibiotic usage, including targeted antibiotic therapy based on microbial culture and sensitivity testing, shorter treatment periods, and combination therapy as per the requirements.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The dacryocystitis market size was valued at USD 40.6 million in 2023 and is anticipated to grow at 5.2% CAGR from 2024

The surgery segment in the market held 62.2% revenue share in 2023, as it offers long-term management of the condition and high success rate.

North America dacryocystitis market held 41.6% share in 2023 and will generate a revenue of USD 25.7 million by 2032, attributed to the presence of advanced treatment facilities for offering minimally invasive treatment options, such as endoscopic dacryocystorhinostomy.

AbbVie Inc. (Allergan), Alcon Inc., Aurolab, Bausch Health Companies Inc., Bayer AG, BVM Medical Limited, F. Hoffmann-La Roche Ltd (Genentech, Inc.), FCI Ophthalmics, Gunther Weiss Scientific Glassblowing Co., Inc., Heart Medical Europe BV, and Kaneka Corporation.